LLY

786.72

-0.78%↓

JNJ

151.39

-0.93%↓

NVO

74.45

+0.12%↑

ABBV

186.36

+0.3%↑

UNH

309.68

+0.87%↑

LLY

786.72

-0.78%↓

JNJ

151.39

-0.93%↓

NVO

74.45

+0.12%↑

ABBV

186.36

+0.3%↑

UNH

309.68

+0.87%↑

LLY

786.72

-0.78%↓

JNJ

151.39

-0.93%↓

NVO

74.45

+0.12%↑

ABBV

186.36

+0.3%↑

UNH

309.68

+0.87%↑

LLY

786.72

-0.78%↓

JNJ

151.39

-0.93%↓

NVO

74.45

+0.12%↑

ABBV

186.36

+0.3%↑

UNH

309.68

+0.87%↑

LLY

786.72

-0.78%↓

JNJ

151.39

-0.93%↓

NVO

74.45

+0.12%↑

ABBV

186.36

+0.3%↑

UNH

309.68

+0.87%↑

Search

Actinium Pharmaceuticals Inc

Slēgts

1.44 -4.64

Pārskats

Akcijas cenas izmaiņa

24h

Šī brīža

Min

1.42

Max

1.52

Galvenie mērījumi

By Trading Economics

Ienākumi

-9.3M

-16M

EPS

-0.51

Darbinieki

31

EBITDA

-9.3M

-17M

Rekomendācijas

By TipRanks

Rekomendācijas

Pirkt (spēcīgs)

Prognoze 12 mēnešiem

+292.16% upside

Dividendes

By Dow Jones

Nākamie ieņēmumi

2025. g. 1. aug.

Tirgus statistika

By TradingEconomics

Tirgus kapitalizācija

-624K

48M

Iepriekšējā atvēršanas cena

6.08

Iepriekšējā slēgšanas cena

1.44

Actinium Pharmaceuticals Inc Grafiks

Pagātnes rezultāti nav uzticams nākotnes rezultātu rādītājs.

Saistītās ziņas

2025. g. 17. jūn. 14:44 UTC

Iegādes, apvienošanās, pārņemšana

Justice Department Orders Safran to Sell Assets to Proceed with Buy of Collins Aerospace Business

2025. g. 17. jūn. 23:43 UTC

Tirgus saruna

Nikkei May Fall Amid Uncertainty Over Israel-Iran Conflict -- Market Talk

2025. g. 17. jūn. 23:34 UTC

Tirgus saruna

Gold Steady, Underpinned by Ongoing Geopolitical Tensions -- Market Talk

2025. g. 17. jūn. 23:22 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. jūn. 23:22 UTC

Tirgus saruna

Global Energy Roundup: Market Talk

2025. g. 17. jūn. 23:22 UTC

Tirgus saruna

Meridian Energy Set to Draw Line Under 'Annus Horribilis' -- Market Talk

2025. g. 17. jūn. 23:17 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Tourism Holdings Likely to Seek Higher Offer -- Market Talk

2025. g. 17. jūn. 23:05 UTC

Tirgus saruna

Fletcher Building Could Signal Improved Shareholder Returns -- Market Talk

2025. g. 17. jūn. 23:05 UTC

Tirgus saruna

Global Equities Roundup: Market Talk

2025. g. 17. jūn. 22:58 UTC

Tirgus saruna

Australian Treasurer Chalmers Expected to Outline Second-Term Reform Agenda -- Market Talk

2025. g. 17. jūn. 22:55 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

XRG Has a Good Argument for Regulatory Approval of Santos Deal -- Market Talk

2025. g. 17. jūn. 22:31 UTC

Tirgus saruna
Iegādes, apvienošanās, pārņemšana

Lifeway Foods CEO Not Surprised by Takeover Interest -- Market Talk

2025. g. 17. jūn. 22:14 UTC

Galvenie tirgus virzītāji

Bitdeer Technologies Group Shares Fall on Note Offering

2025. g. 17. jūn. 19:49 UTC

Tirgus saruna

Natural Gas Slow Down Gains -- Market Talk

2025. g. 17. jūn. 19:34 UTC

Tirgus saruna

Oil Rises On Israel-Iran Conflict Uncertainty -- Market Talk

2025. g. 17. jūn. 19:10 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

2025. g. 17. jūn. 19:10 UTC

Tirgus saruna

Dollar Strengthens, Treasury Yields Fall in Risk-Off Trade -- Market Talk

2025. g. 17. jūn. 18:41 UTC

Tirgus saruna

Slowdown in US Consumer Spending Expected -- Market Talk

2025. g. 17. jūn. 18:15 UTC

Tirgus saruna

Gold Inches Down as Profit-Taking Seen -- Market Talk

2025. g. 17. jūn. 17:44 UTC

Tirgus saruna

Analysts Forecast Record-High Ethanol Output -- Market Talk

2025. g. 17. jūn. 16:37 UTC

Tirgus saruna

A Buy-Canadian Policy Could Support Steel Producers -- Market Talk

2025. g. 17. jūn. 16:30 UTC

Tirgus saruna

Market Talk Roundup: Latest on U.S. Politics

2025. g. 17. jūn. 16:30 UTC

Tirgus saruna

Canada Seen Likely to Drop Digital-Services Tax -- Market Talk

2025. g. 17. jūn. 16:15 UTC

Tirgus saruna

Global Commodities Roundup: Market Talk

2025. g. 17. jūn. 16:15 UTC

Tirgus saruna

Base Metal Prices Mixed on Risk-Off Sentiment -- Market Talk

2025. g. 17. jūn. 16:12 UTC

Tirgus saruna

Gold Futures Fall as Safe-haven Demand Retreats -- Market Talk

2025. g. 17. jūn. 14:54 UTC

Tirgus saruna

Oil Rises on Continued Israel-Iran Conflict -- Market Talk

2025. g. 17. jūn. 14:47 UTC

Tirgus saruna

European Gas Climbs on Middle East Risks, EU Russian Ban Proposal -- Market Talk

2025. g. 17. jūn. 14:41 UTC

Tirgus saruna

Natural Gas Extends Climb -- Market Talk

2025. g. 17. jūn. 14:40 UTC

Tirgus saruna

Global Forex and Fixed Income Roundup: Market Talk

Salīdzinājums

Cenas izmaiņa

Actinium Pharmaceuticals Inc Prognoze

Cenas mērķis

By TipRanks

292.16% augšup

Prognoze 12 mēnešiem

Vidējais 6 USD  292.16%

Augstākais 9 USD

Zemākais 4 USD

Pamatojoties uz 3 Volstrītas analītiķiem, kuri piedāvā 12 mēnešu cenu mērķi Actinium Pharmaceuticals Inc — pēdējo 3 mēnešu laikā.

Vērtējuma vienprātība

By TipRanks

Pirkt (spēcīgs)

3 ratings

3

Pirkt

0

Turēt

0

Pārdot

Finanšu rādītāji

Pārdošanas un administrēšanas izmaksas

Darbības izmaksas

Peļņa pirms nodokļu nomaksas

Pārdošana

Pārdošanas maksa

Bruto peļņa no pārdošanas

Procentu izdevumi par parādu

EBITDA

Pamatdarbības peļņa

$

Par Actinium Pharmaceuticals Inc

Actinium Pharmaceuticals, Inc. develops antibody radiation conjugates and other targeted radiotherapies intended to improve outcomes for people who have failed existing oncology therapies. Its Iomab-B is an induction and conditioning agent prior to bone marrow transplant in patients with relapsed and refractory acute myeloid leukemia (r/r AML). The company focuses on advancing its development for product candidate Actimab-A, a therapeutic agent that has demonstrated potential activity in r/r AML patients. In addition, it engages with the National Cancer Institute under the cooperative research and development agreement for the development of Actimab-A in AML and other myeloid malignancies. Its Iomab-ACT, a next generation conditioning candidate, is being developed for improving patient access and outcomes for curative cell and gene therapies. Further, the company's research and development activities primarily focus on advancing various preclinical programs for solid tumor indications. The company holds approximately 235 patents and patent applications, including various patents related to the manufacture of the isotope Ac-225 in a cyclotron. The company is based in New York, New York.